Clinigen Group plc (AIM: CLIN) has acquired the global rights to Proleukin (aldesleukin, recombinant interleukin-2) outside the United States from Swiss-based Novartis International AG (VTX: NOVN), the pharmaceutical company announced on Tuesday.
Financial terms of the deal were not disclosed.
Proleukin is licensed in around 20 countries and is primarily indicated for use in metastatic renal cell carcinoma, as well as for metastatic melanoma in certain markets. The drug is also currently being investigated in clinical trials at varying dose levels and in combination with other licensed and developmental pharmaceutical products.
Clinigen said it will seek to revitalise sales of Proleukin by working with healthcare professionals to ensure its benefit to patients is well understood and by making the drug available to those who need it. The company is also investigating the opportunity to develop new dosage presentations and potential product combinations.
Clinigen views Proleukin as a good fit with its current Commercial Medicines portfolio of products in the oncology and infectious disease therapy areas.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886